Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCA study of esomeprazole and Coca-Cola effects on capecitabine absorption
2017-004465-27Phase 4Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine and esomeprazole in colorectal cancer (CRC) and Nonhematologic neoplasms, sponsored by Erasmus MC Cancer Institute. Primary endpoint: Area under the plasma concentration-time curve of capecitabine. Started Dec 2017; status: completed.
02
Drugs
capecitabineesomeprazole
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2017-004465-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004465-27.